Clinical Trial Update: Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of recombinant adenovirus for non-muscle invasive bladder cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma in Situ
• Non-muscle Invasive Bladder Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• Recombinant adenovirus (recombinant adenovirus)

Snippet

Sponsor: CG Oncology, Inc. | Conditions: Transitional Cell Carcinoma, Bladder Cancer | Phase 2, Phase 3 | Status: TERMINATED